Novavax Inc header image

Novavax Inc

NVAX

Equity

ISIN null / Valor 47862952

NASDAQ (2026-03-27)
USD 8.45-5.59%

Novavax Inc
UMushroom community rating:

star star star star star
2.64 5 votes No rating yet
NegativeNeutralPositive

About company

Novavax Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Leveraging proprietary recombinant nanoparticle vaccine technology, Novavax has been at the forefront of developing vaccines for a range of infectious diseases, including its notable efforts in creating a vaccine for COVID-19. The company's approach combines the power of genetic engineering and nanoparticle technology to produce vaccine candidates aimed at eliciting robust immune responses. While the company has gained significant attention for its work during the COVID-19 pandemic, its research and development efforts extend to other infectious diseases as well, positioning Novavax as a key player in the global effort to combat emerging health threats through vaccination.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

16.4%1Y
38.8%3Y
-95.4%5Y

Performance

75.5%1Y
95.4%3Y
103%5Y

Volatility

Market cap

1377 M

Market cap (USD)

Daily traded volume (Shares)

3,942,822

Daily traded volume (Shares)

1 day high/low

8.2 / 7.7

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

2.64

5 votes
Performance:
starstarstarstarstar
3.09
Innovation:
starstarstarstarstar
3.36
Society:
starstarstarstarstar
3.55
Nature:
starstarstarstarstar
2.64
Nicolas Allet
Switzerland, 18 Mar 2026
star star star star star
Novavax faces ongoing financial headwinds as COVID demand fades. The Sanofi partnership offers a lifeline but uncertainty remains high. Protein subunit platform is differentiated yet commercialization beyond COVID is still unproven.
Réka Vass
Switzerland, 28 Mar 2025
star star star star star
Robin Roten
Switzerland, 04 Dec 2022
star star star star star

EQUITIES OF THE SAME SECTOR

AppLovin Corp
AppLovin Corp AppLovin Corp Valor: 110387675
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.56%USD 381.20
Embracer Group AB
Embracer Group AB Embracer Group AB Valor: 113946352
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.71%SEK 46.59
Team17 Group PLC
Team17 Group PLC Team17 Group PLC Valor: 41724468
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.78%GBP 2.10
Dun & Bradstreet Holdings Inc
Dun & Bradstreet Holdings Inc Dun & Bradstreet Holdings Inc Valor: 55336960
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%USD 9.15
MercadoLibre Inc
MercadoLibre Inc MercadoLibre Inc Valor: 3109814
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.93%USD 1,599.52
Kingsoft Cloud Holdings Ltd
Kingsoft Cloud Holdings Ltd Kingsoft Cloud Holdings Ltd Valor: 54578933
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-5.63%USD 13.59
Diodes Inc
Diodes Inc Diodes Inc Valor: 925057
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.94%USD 68.20
GLOBALFOUNDRIES INC
GLOBALFOUNDRIES INC GLOBALFOUNDRIES INC Valor: 114166096
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.66%USD 42.94
Extreme Networks Inc
Extreme Networks Inc Extreme Networks Inc Valor: 653096
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.29%USD 15.26
LS Telcom AG
LS Telcom AG LS Telcom AG Valor: 1197053
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%EUR 3.48